ADTX · As filed with the SEC
Aditxt cash flow statement, by fiscal year
The statement as Aditxt presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | (42,787,043) | (35,020,058) | (32,390,447) | (27,649,876) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||||
| Stock-based compensation | 473,311 | 33,071 | 1,402,018 | 3,131,368 |
| Stock-based compensation from asset purchase | 10,000 | 6,712,663 | — | — |
| Depreciation expense | 269,271 | 613,918 | 435,027 | 428,977 |
| Amortization of intangible assets | 3,333 | 3,333 | 107,556 | 107,000 |
| Amortization of debt discount | — | — | — | 1,533,048 |
| Amortization of debt discount | — | — | 2,821,629 | — |
| Amortization of debt discount - note payable | 1,706,697 | 3,174,920 | — | — |
| Amortization of debt discount - note receivable | (220,689) | — | — | — |
| Loss on note exchange agreement | — | 208,670 | — | — |
| Modifications of warrants as debt issuance costs | — | 376,901 | — | — |
| New principal from extension of notes, net of debt discount | — | 451,974 | — | — |
| Change in fair value of derivative liability | (14,515) | (414,501) | — | — |
| Change in fair value of Evofem warrants | (2,806,983) | — | — | — |
| Impairment of Evofem F-1 preferred stock | 23,766,209 | — | — | — |
| Disposal of fixed assets | — | 3,000 | — | — |
| Gain on note exchange agreement | — | — | (51,712) | — |
| Impairment on notes receivable | — | — | — | 543,938 |
| Disposal of fixed assets | — | — | — | 6,976 |
| Bargain purchase gain from purchase of Evofem convertible notes | (328,071) | — | — | — |
| Impairment of fixed assets | 412,005 | — | — | — |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | 43,435 | 364,891 | 119,635 | (36,767) |
| Prepaid expenses | (613,983) | 214,011 | 279,479 | 23,884 |
| Deposits | — | — | 248,956 | (438,117) |
| Deposits | 26,086 | 18,738 | — | — |
| Inventory | 5,471 | 734,257 | 204,591 | (455,396) |
| Accounts payable and accrued expenses | (5,632,893) | 5,095,091 | 6,646,457 | 412,959 |
| Settlement liability | — | 667,000 | 1,600,000 | — |
| Net cash used in operating activities | (25,688,359) | (16,762,121) | (18,576,811) | (22,392,006) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Purchase of fixed assets | — | — | — | (367,079) |
| Tenant improvement allowance receivable | — | — | — | 125,161 |
| Purchase of fixed assets | (13,743) | — | (14,407) | — |
| Investment in convertible notes receivable and warrants | (2,425,000) | — | — | — |
| Investment in Evofem F-1 preferred stock | — | (5,000,000) | — | — |
| Net cash used in investing activities | (2,438,743) | (5,000,000) | (14,407) | (241,918) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from note payable - related party | — | — | — | 80,000 |
| Proceeds from notes payable, related party | 678,000 | 467,000 | 1,062,523 | — |
| Proceeds from notes and convertible notes payable, net of offering costs | 1,191,018 | 4,149,153 | 7,903,445 | — |
| Repayments of note payable - related party | — | — | (687,523) | — |
| Repayments of note payable, related party | (793,000) | (727,000) | — | (3,206,887) |
| Sale of Series B Preferred shares to related party | — | — | — | 20,000 |
| Redemption of Series B Preferred shares to related party | — | — | — | (20,000) |
| Repayments of note payable | (6,613,882) | (5,287,942) | (3,152,488) | (80,000) |
| Proceeds from notes and convertible notes payable, net of offering costs | — | — | — | 2,795,000 |
| Series C Preferred Shares | — | — | 1,000 | — |
| Series C Preferred Shares | — | — | (1,000) | — |
| Common stock, preferred stock, and warrants issued for cash, net of issuance costs | 44,128,225 | 21,166,343 | — | — |
| Cash from subscription receivable | 1,108,751 | 4,335,877 | — | — |
| Payments on financing on fixed asset | — | — | (262,160) | (400,491) |
| Proceeds from exercises of warrants | — | 1,246,490 | 1,000 | 1,109,574 |
| Redemptions of C-1 preferred stock | — | (2,851,839) | — | — |
| Redemptions of D-1 preferred stock | — | (32) | — | — |
| Redemptions of A-1 preferred stock | (308,000) | — | — | — |
| Redemptions of C-1 preferred stock | (8,898,442) | — | — | — |
| Net cash provided by financing activities | 30,492,670 | 22,498,050 | 15,919,680 | 17,530,503 |
| NET DECREASE IN CASH | — | — | — | (5,103,421) |
| NET INCREASE IN CASH | 2,365,568 | 735,929 | (2,671,538) | — |
| CASH AT BEGINNING OF PERIOD | 833,031 | 97,102 | 2,768,640 | 7,872,061 |
| CASH AT END OF PERIOD | 3,198,599 | 833,031 | 97,102 | 2,768,640 |
| Common stock and warrants issued for cash, net of issuance costs | — | — | 11,054,883 | 17,233,307 |
| Supplemental cash flow information: | ||||
| Cash paid for interest expense | — | — | — | 753,038 |
| Cash paid for interest | 2,465,546 | 1,235,640 | 2,726,020 | — |
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||||
| Issuance of shares for the conversion of notes payable | — | 500,000 | — | — |
| Debt discount from shares issued as inducement for note payable | — | 1,576,431 | — | — |
| Shares issued for debt offering costs | — | — | 354,838 | — |
| Warrant modification | — | 5,907,011 | 319,871 | — |
| Issuance of shares in asset purchase | — | 266,448 | — | — |
| Shares issued for settlement | — | 1,600,000 | — | — |
| Shares issued for settlement | — | — | — | 80,000 |
| Debt discount from warrants issued with convertible note payable | — | — | — | 878,622 |
| Shares issued for debt offering costs | — | — | — | 96,030 |
| Warrant modification | — | — | — | 37,677 |
| Deferred issuance costs | — | — | — | 50,000 |
| Return of notes payable from Evofem merger agreement | — | 11,174,426 | — | — |
| Issuance of shares of Pearsanta Common Stock for IP | — | — | 10,000 | — |
| Assumption of notes payable from Evofem merger agreement | — | — | 11,173,750 | — |
| Series A-1 Preferred shares issued for exchange agreement | — | — | 22,277,233 | — |
| Accrued intertest rolled into notes payable | — | — | 701,315 | — |
| Series B-2 Preferred shares issued in note exchange agreement | — | — | 2,686,306 | — |
| Accrued interest rolled into notes payable | 33,752 | 538,223 | — | — |
| Exchange of warrants for Series C-1 convertible preferred stock | — | 6,000,000 | — | — |
| Settlement of liability for Series C-1 Convertible Preferred Stock | — | 667,000,000,000 | — | — |
| Derivative liability from conversion feature on preferred stock | — | 429,018 | — | — |
| ELOC payable | 328,071 | — | — | — |
| Series C-1 redemption payable | 237,498 | 1,354,774 | — | — |
| ELOC commitment fee stock payable | 2,250,000 | 2,250,000 | — | — |
| Loan in escrow | 2,000,000 | — | — | — |
| Reclassification of series A-1 preferred shares to liabilities | 517,444 | — | — | — |
| Write off of financed asset | 147,823 | — | — | — |
| Initial recognition of lease liability and right of use asset | 800,359 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.